TY  - JOUR
AU  - Saksida, Tamara
AU  - Vujičić, Milica
AU  - Nikolić, Ivana
AU  - Stojanović, Ivana D.
AU  - Haegeman, G.
AU  - Stošić-Grujičić, Stanislava
PY  - 2014
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/2111
AB  - Background and PurposeType 1 diabetes is a multifactorial inflammatory
   disease that develops as a result of deregulated immune responses,
   causing progressive autoimmune destruction of insulin-producing beta
   cells of pancreas. 2-((4-acetoxyphenyl)-2-chloro-N-methyl) ethylammonium
   chloride, compound A (CpdA), is a selective glucocorticoid receptor (GR)
   agonist that displays strong anti-inflammatory and immunomodulatory
   activities. We investigated the therapeutic effectiveness of CpdA in a
   pharmacological model of type 1 diabetes in mice.
   Experimental ApproachThe utility of CpdA in diabetes prevention was
   evaluated in vivo through its prophylactic administration to male
   C57BL/6 mice that received multiple low doses of streptozotocin for
   immunoinflammatory diabetes induction. The effect of CpdA on disease
   development was studied by measuring blood glucose and insulin level,
   histopathological examination, determination of the nature of
   infiltrating cells, pro- and anti-inflammatory cytokine production, and
   signalling pathways.
   Key ResultsProphylactic in vivo therapy with CpdA conferred protection
   against development of immunoinflammatory diabetes in mice by dampening
   the M1/Th1/Th17 immune response and switching it towards an
   anti-inflammatory M2/Th2/Treg profile, thus preserving beta cell
   function.
   Conclusions and ImplicationsAnti-diabetic properties of CpdA are
   mediated through modulation of immune cell-mediated pathways, but
   without triggering adverse events. These findings provide basic
   information for the therapeutic use of selective GR agonists in the
   amelioration of islet-directed autoimmunity.
T2  - British Journal of Pharmacology
T1  - Compound A, a selective glucocorticoid receptor agonist, inhibits
 immunoinflammatory diabetes, induced by multiple low doses of
 streptozotocin in mice
IS  - 24, SI
VL  - 171
DO  - 10.1111/bph.12892
SP  - 5898
EP  - 5909
ER  - 

@article{
author = "Saksida, Tamara and Vujičić, Milica and Nikolić, Ivana and Stojanović, Ivana D. and Haegeman, G. and Stošić-Grujičić, Stanislava",
year = "2014",
abstract = "Background and PurposeType 1 diabetes is a multifactorial inflammatory
   disease that develops as a result of deregulated immune responses,
   causing progressive autoimmune destruction of insulin-producing beta
   cells of pancreas. 2-((4-acetoxyphenyl)-2-chloro-N-methyl) ethylammonium
   chloride, compound A (CpdA), is a selective glucocorticoid receptor (GR)
   agonist that displays strong anti-inflammatory and immunomodulatory
   activities. We investigated the therapeutic effectiveness of CpdA in a
   pharmacological model of type 1 diabetes in mice.
   Experimental ApproachThe utility of CpdA in diabetes prevention was
   evaluated in vivo through its prophylactic administration to male
   C57BL/6 mice that received multiple low doses of streptozotocin for
   immunoinflammatory diabetes induction. The effect of CpdA on disease
   development was studied by measuring blood glucose and insulin level,
   histopathological examination, determination of the nature of
   infiltrating cells, pro- and anti-inflammatory cytokine production, and
   signalling pathways.
   Key ResultsProphylactic in vivo therapy with CpdA conferred protection
   against development of immunoinflammatory diabetes in mice by dampening
   the M1/Th1/Th17 immune response and switching it towards an
   anti-inflammatory M2/Th2/Treg profile, thus preserving beta cell
   function.
   Conclusions and ImplicationsAnti-diabetic properties of CpdA are
   mediated through modulation of immune cell-mediated pathways, but
   without triggering adverse events. These findings provide basic
   information for the therapeutic use of selective GR agonists in the
   amelioration of islet-directed autoimmunity.",
journal = "British Journal of Pharmacology",
title = "Compound A, a selective glucocorticoid receptor agonist, inhibits
 immunoinflammatory diabetes, induced by multiple low doses of
 streptozotocin in mice",
number = "24, SI",
volume = "171",
doi = "10.1111/bph.12892",
pages = "5898-5909"
}

Saksida, T., Vujičić, M., Nikolić, I., Stojanović, I. D., Haegeman, G.,& Stošić-Grujičić, S.. (2014). Compound A, a selective glucocorticoid receptor agonist, inhibits
 immunoinflammatory diabetes, induced by multiple low doses of
 streptozotocin in mice. in British Journal of Pharmacology, 171(24, SI), 5898-5909.
https://doi.org/10.1111/bph.12892

Saksida T, Vujičić M, Nikolić I, Stojanović ID, Haegeman G, Stošić-Grujičić S. Compound A, a selective glucocorticoid receptor agonist, inhibits
 immunoinflammatory diabetes, induced by multiple low doses of
 streptozotocin in mice. in British Journal of Pharmacology. 2014;171(24, SI):5898-5909.
doi:10.1111/bph.12892 .

Saksida, Tamara, Vujičić, Milica, Nikolić, Ivana, Stojanović, Ivana D., Haegeman, G., Stošić-Grujičić, Stanislava, "Compound A, a selective glucocorticoid receptor agonist, inhibits
 immunoinflammatory diabetes, induced by multiple low doses of
 streptozotocin in mice" in British Journal of Pharmacology, 171, no. 24, SI (2014):5898-5909,
https://doi.org/10.1111/bph.12892 . .